Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe


  Rheumatoid Arthritis

  Free Subscription


11.05.2020

8 Ann Rheum Dis
3 Arthritis Res Ther
1 Clin Exp Rheumatol
1 Clin Rheumatol
1 Drugs
1 J Rheumatol
1 PLoS One
1 Rheumatol Int
3 Scand J Rheumatol
1 Z Rheumatol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Rheum Dis

  1. ZHAO SS, Lyu H, Solomon DH, Yoshida K, et al
    Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework.
    Ann Rheum Dis. 2020 May 7. pii: annrheumdis-2020-217200.
    PubMed         Abstract available

  2. OUYANG F
    When binary and continuous responses disagree.
    Ann Rheum Dis. 2020;79:e38.
    PubMed        

  3. LAUPER K, Courvoisier DS, Gabay C
    Response to: 'When binary and continuous responses disagree' by Dr Ouyang.
    Ann Rheum Dis. 2020;79:e39.
    PubMed        

  4. AUNGIER S, Cartwright AJ, Schwenzer A, Marshall J, et al
    Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al.
    Ann Rheum Dis. 2020;79:e43.
    PubMed        

  5. ATTUR M, Zhou H, Samuels J, Krasnokutsky S, et al
    Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.
    Ann Rheum Dis. 2020;79:400-407.
    PubMed         Abstract available

  6. VAN DER HELM-VAN MIL A, Landewe RBM
    The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.
    Ann Rheum Dis. 2020;79:312-315.
    PubMed         Abstract available

  7. GUO J, Zhang T, Li X, Cao H, et al
    Response to: 'Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al' by Regueiro and Gonzalez.
    Ann Rheum Dis. 2020 May 5. pii: annrheumdis-2020-217064.
    PubMed        

  8. SHAFRAN IH, Alasti F, Smolen JS, Aletaha D, et al
    Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
    Ann Rheum Dis. 2020 May 5. pii: annrheumdis-2019-215987.
    PubMed         Abstract available


    Arthritis Res Ther

  9. ZHANG H, Zhang H, Gao D, Xie W, et al
    Overlapping Sjogren's syndrome reduces the probability of reaching target in rheumatoid arthritis patients: a propensity score matched real-world cohort from 2009 to 2019.
    Arthritis Res Ther. 2020;22:100.
    PubMed         Abstract available

  10. JARLBORG M, Courvoisier DS, Lamacchia C, Martinez Prat L, et al
    Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.
    Arthritis Res Ther. 2020;22:105.
    PubMed         Abstract available

  11. SONG YJ, Choi IA, Meylan F, Demoruelle MK, et al
    Circulating TNF-like protein 1A (TL1A) is elevated early in rheumatoid arthritis and depends on TNF.
    Arthritis Res Ther. 2020;22:106.
    PubMed         Abstract available


    Clin Exp Rheumatol

  12. KUMAR R, Piantoni S, Boldini M, Garrafa E, et al
    Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept.
    Clin Exp Rheumatol. 2020 Apr 27. pii: 15133.
    PubMed         Abstract available


    Clin Rheumatol

  13. EL OUALI Z, Nassar K, Janani S
    Rheumatoid arthritis and myelodysplastic syndrome: a fortuitous association?
    Clin Rheumatol. 2020 May 2. pii: 10.1007/s10067-020-05092.
    PubMed        


    Drugs

  14. MELVILLE AR, Kearsley-Fleet L, Buch MH, Hyrich KL, et al
    Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach.
    Drugs. 2020 May 2. pii: 10.1007/s40265-020-01309.
    PubMed         Abstract available


    J Rheumatol

  15. TURK MA, Hayworth JL, Nevskaya T, Pope JE, et al
    Ocular manifestations in rheumatoid arthritis, connective tissue disease and vasculitis: a systematic review and meta-analysis.
    J Rheumatol. 2020 May 1. pii: jrheum.190768. doi: 10.3899/jrheum.190768.
    PubMed         Abstract available


    PLoS One

  16. AVOUAC J, Cauvet A, Steelandt A, Shirai Y, et al
    Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease.
    PLoS One. 2020;15:e0232978.
    PubMed         Abstract available


    Rheumatol Int

  17. LINDNER L, Callhoff J, Alten R, Krause A, et al
    Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007-2017.
    Rheumatol Int. 2020 May 6. pii: 10.1007/s00296-020-04593.
    PubMed         Abstract available


    Scand J Rheumatol

  18. HEUS A, Arends S, Van Nimwegen JF, Stel AJ, et al
    Pulmonary involvement in primary Sjogren's syndrome, as measured by the ESSDAI.
    Scand J Rheumatol. 2020;49:38-46.
    PubMed         Abstract available

  19. ORNBJERG LM, Christensen KB, Tennant A, Hetland ML, et al
    Validation and assessment of minimally clinically important difference of the unadjusted Health Assessment Questionnaire in a Danish cohort: uncovering ordinal bias.
    Scand J Rheumatol. 2020;49:1-7.
    PubMed         Abstract available

  20. MINALI PA, Pimentel C, de Mello MT, Lima G, et al
    Effectiveness of resistance exercise in functional fitness in women with primary Sjogren's syndrome: randomized clinical trial.
    Scand J Rheumatol. 2020;49:47-56.
    PubMed         Abstract available


    Z Rheumatol

  21. LEE YH, Song GG
    Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
    Z Rheumatol. 2020 May 4. pii: 10.1007/s00393-020-00796.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: